Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein

Table 1 In vitro anti-HIV-1 activity of triptolide

Virus	Cell type	Measurement	EC₅₀(nM)^a	CC₅₀(nM)^b	SI^c
HIV-1 NL4-3	TZM-bl	Luciferase	0.32	25.4	79.4
HIV-1-Luc	Jurkat	Luciferase	0.45	13.9	30.9
HIV-1 NL4-3	PBMC donor A	p24	1.1^d	12.6	11.5
HIV-1 NL4-3	PBMC donor B	p24	0.9^d	15.3	17.0
HIV-1 NL4-3	PBMC donor C	p24	1.3^d	11.2	8.6
HIV-1 LAI	PBMC donor A	p24	1.5^d	12.6	8.4
HIV-1 LAI	PBMC donor B	p24	1.2^d	15.3	12.8
HIV-1 LAI	PBMC donor C	p24	1.5^d	11.2	7.5
HIV-1 BaL	PBMC donor A	p24	1.4^d	12.6	9.0
HIV-1 BaL	PBMC donor B	p24	1.6^d	15.3	9.6
HIV-1 BaL	PBMC donor C	p24	1.0^d	11.2	11.2

^aCompound concentration required to reduce the production of luciferase or p24 antigen by 50%.
^bCompound concentration required to reduce mock-infected cell viability by 50%.
^cSelective index, ratio of CC₅₀/EC₅₀.
^dEC₅₀ value was calculated based on p24 inhibition at day 6 post-infection.

ISSN: 1742-4690